Serious arterial thromboembolic events (sATE) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizurnab (BV): results from the BRITE registry

被引：0
|
作者：
Sing, A. [1 ]
Sugrue, M. [1 ]
Chiruvolu, R. [1 ]
Yi, J. [1 ]
Purdie, D. [1 ]
Dong, W. [1 ]
Grothey, A. [2 ]
Kozloff, M. [3 ]
机构：
[1] Genentech Inc, San Francisco, CA USA
[2] Mayo Clin, Rochester, MN USA
[3] Univ Chicago, Ingalls Hosp, Harvey, KS USA
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70973-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3045
引用
收藏
页码：249 / 249
页数：1
相关论文
共 50 条
  • [31] Evaluation of quality of life (QoL) in patients (pts) with metastatic colorectal cancer (MCRC) treated with capecitabine (X)
    Segalla, J
    van Eyll, B
    Federico, M
    Perdicaris, M
    Cabral, S
    Skare, N
    Saltz, E
    Moura, G
    Filho, U
    Franke, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 751S - 751S
  • [32] Serious wound healing complications (SWHC) following surgery in patients with metastatic colorectal cancer (RNCRC) receiving bevacizumab (BV): Results from the brite observational cohort study (OCS)
    Sugrue, M.
    Purdie, D.
    Feng, S.
    Flynn, P.
    Grothey, A.
    Sargent, D.
    Berlin, J.
    Kabbinavar, F.
    Dong, W.
    Kozoff, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 82 - 83
  • [33] Extended RAS analysis in patients (pts) with untreated metastatic colorectal cancer (mCRC): Results from the PRIME and PEAK studies
    Hecht, J. Randolph
    Douillard, Jean-Yves
    Schwartzberg, Lee
    Siena, Salvatore
    Tabernero, Josep
    Karthaus, Meinholf
    Rivera, Fernando
    Oliner, Kelly S.
    Yu, Hua
    Tian, Ying
    Jung, Scott
    Go, Will
    MOLECULAR CANCER RESEARCH, 2014, 12
  • [34] Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry
    Li Chia Chong
    Jennifer E. Hardingham
    Amanda R. Townsend
    Cynthia Piantadosi
    Gonzalo Tapia Rico
    Chris Karapetis
    Rob Padbury
    Guy Maddern
    Amitesh Roy
    Timothy J. Price
    Targeted Oncology, 2020, 15 : 751 - 757
  • [35] Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry
    Chong, Li Chia
    Hardingham, Jennifer E.
    Townsend, Amanda R.
    Piantadosi, Cynthia
    Rico, Gonzalo Tapia
    Karapetis, Chris
    Padbury, Rob
    Maddern, Guy
    Roy, Amitesh
    Price, Timothy J.
    TARGETED ONCOLOGY, 2020, 15 (06) : 751 - 757
  • [36] Defective mismatch repair (dMMR) status as a predictive biomarker in Chinese patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV) plus chemotherapy.
    Ling, Jiayu
    Chen, Dianke
    Zhang, Jianwei
    Zhong, Lixing
    Cai, Yue
    Deng, Yanhong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [37] Characteristics of long-versus short-surviving patients (Pts): An analysis of the ARIES Observational Cohort Study (OCS) of bevacizumab (BV)-treated pts with metastatic colorectal cancer (mCRC).
    Kozloff, Mark
    Grothey, Axel
    Bendell, Johanna C.
    Cohn, Allen Lee
    Bekaii-Saab, Tanios S.
    Roach, Nancy
    Flick, Elizabeth Dawn
    Mun, Yong
    Fish, Susan Meredith
    Laeufle, Rita
    Sommer, Nicolas
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [38] VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
    Loupakis, F.
    Ruzzo, A.
    Salvatore, L.
    Canestrari, E.
    Cremolini, C.
    Santini, D.
    Bencardino, K.
    Manzoni, M.
    Falcone, A.
    Graziano, F.
    EJC SUPPLEMENTS, 2009, 7 (02): : 357 - 357
  • [39] Sunitinib (S) in patients (Pts) with metastatic colorectal cancer (mCRC) with FLT-3 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Alvarez, Ricardo H.
    Garrett-Mayer, Elizabeth
    Halabi, Susan
    Mangat, Pam K.
    Al Baghdadi, Tareq
    Ahn, Eugene R.
    Chai, Seungjean
    Rygiel, Andrew L.
    Antonelli, Kaitlyn R.
    Islam, Samiha
    Bruinooge, Suanna S.
    Schilsky, Richard L.
    CANCER RESEARCH, 2019, 79 (13)
  • [40] VEGF GENE POLYMORPHISMS IN THE PREDICTION OF BENEFIT FROM FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Loupakis, F.
    Ruzzo, A.
    Salvatore, L.
    Canestrari, E.
    Cremolini, C.
    Masi, G.
    Schirripa, M.
    Spoto, C.
    Galluccio, N.
    Vincenzi, B.
    Santini, D.
    Bencardino, K.
    Ricci, V
    Catalano, V
    Manzoni, M.
    Danova, M.
    Tonini, G.
    Magnani, M.
    Falcone, A.
    Graziano, F.
    ANNALS OF ONCOLOGY, 2009, 20
12345